Antitumor Activity of Margetuximab (M) Plus Pembrolizumab (P) in Patients (pts) with Advanced HER2+ (IHC3+) Gastric Carcinoma (GC).
Journal of clinical oncology(2019)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined